Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W4024

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:08:29 2024-04-25 am EDT			5-day change	1st Jan Change
0.692 ^USD	+3.13%		+7.43%	-9.84%

Apr. 22	Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762	CI
Apr. 16	Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology	CI

Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2020

May 12, 2020 at 04:38 pm EDT

Phio Pharmaceuticals Corp. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced sales was USD 0 compared to USD 21,000 a year ago. Operating loss was USD 2.356 million compared to USD 2.146 million a year ago. Net loss was USD 2.351 million compared to USD 2.119 million a year ago. Basic loss per share from continuing operations was USD 1.33 compared to USD 5.71 a year ago.

Latest news about Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762	Apr. 22	CI
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology	Apr. 16	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	Mar. 21	CI
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research	Mar. 13	CI
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders	Mar. 06	MT
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders	Mar. 06	CI
HC Wainwright Adjusts Price Target on Phio Pharmaceuticals to $4 From $6, Keeps Buy Rating	Feb. 06	MT
Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas	Nov. 09	CI
Phio Pharmaceuticals Shares Rise After Data Shows Intasyl Compound Enhances Tumor Control	Nov. 03	MT
Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer	Nov. 03	CI
Top Premarket Decliners	23-10-12	MT
Top Midday Gainers	23-10-11	MT
Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894	23-10-11	CI
Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute	23-08-21	CI
Phio Pharmaceuticals Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Phio Pharmaceuticals Completes $4 Million Securities Offering	23-06-02	MT
Phio Pharmaceuticals Corp. announced that it has received $3.999998 million in funding	23-06-01	CI
Phio Pharmaceuticals to Raise $4 Million From Securities Offering; Shares Fall	23-05-31	MT
Phio Pharmaceuticals Corp. announced that it expects to receive $3.000002 million in funding	23-05-30	CI
Sector Update: Health Care Stocks Weaker Late Thursday	23-05-18	MT
Sector Update: Health Care Stocks Dropping Thursday Afternoon	23-05-18	MT
Top Midday Gainers	23-05-18	MT

Chart Phio Pharmaceuticals Corp.

Duration

Period

More charts

Company Profile

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cellsâ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - American Society of Gene & Cell Therapy Meeting - Abstract Number:774

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.671 USD

Average target price

4 USD

Spread / Average Target

+496.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHIO PHARMACEUTICALS CORP.	-9.84%	3.08M
IQVIA HOLDINGS INC.	+0.67%	43.84B
MODERNA, INC.	+4.14%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+7.36%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-25.67%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.23%	12.29B
MEDPACE HOLDINGS, INC.	+25.34%	12.29B
UNITED THERAPEUTICS CORPORATION	+6.93%	11.15B

Other Biotechnology & Medical Research